CyanVac LLC
Cyanvac LLC is dedicated to tackling the world's most pressing infectious diseases with easily deliverable vaccines worldwide. They develop intranasal vaccines using a proprietary PIV5-based vector, aiming to block viral transmission and reduce spread. Their vaccines are designed to be easy to administer, transport, and manufacture, with a focus on rapid response to emerging threats and global health challenges.
Industries
CyanVac LLC
Athens, Georgia, United States, North America
Products
Intranasal COVID-19 vaccine candidate
An intranasal viral-vectored vaccine designed to induce mucosal and systemic immunity against SARS-CoV-2 and to be used as a primary vaccine or booster.
Intranasal RSV vaccine program
A live intranasal vaccine expressing full-length RSV F protein intended to protect against respiratory syncytial virus infection.
Intranasal avian influenza vaccine candidates (H5N1, H7N9)
PIV5-based intranasal vaccine candidates shown to protect against H5N1 and H7N9 in animal models, developed for pandemic preparedness.
Intranasal norovirus vaccine candidate
Vaccine candidate targeting norovirus to prevent acute gastroenteritis and associated outbreaks.
Intranasal Lyme disease vaccine candidate
Vaccine candidate against Lyme disease intended to protect populations at risk from tick-borne Borrelia infection.
Additional pathogen vaccine programs
Ongoing assessment and selection of additional pipeline programs based on protective efficacy of the viral-vector platform against multiple pathogens.
Intranasal COVID-19 vaccine candidate
An intranasal viral-vectored vaccine designed to induce mucosal and systemic immunity against SARS-CoV-2 and to be used as a primary vaccine or booster.
Intranasal RSV vaccine program
A live intranasal vaccine expressing full-length RSV F protein intended to protect against respiratory syncytial virus infection.
Intranasal avian influenza vaccine candidates (H5N1, H7N9)
PIV5-based intranasal vaccine candidates shown to protect against H5N1 and H7N9 in animal models, developed for pandemic preparedness.
Intranasal norovirus vaccine candidate
Vaccine candidate targeting norovirus to prevent acute gastroenteritis and associated outbreaks.
Intranasal Lyme disease vaccine candidate
Vaccine candidate against Lyme disease intended to protect populations at risk from tick-borne Borrelia infection.
Additional pathogen vaccine programs
Ongoing assessment and selection of additional pipeline programs based on protective efficacy of the viral-vector platform against multiple pathogens.
Services
Assay development and IND support
Development, qualification, and validation of virology and immunology assays to support IND filings and clinical development.
Preclinical efficacy testing and animal challenge studies
Design and execution of preclinical efficacy and challenge studies across multiple species to evaluate protective responses of vaccine candidates.
Process development and small-scale manufacturing for viral-vectored vaccines
Upstream process development for viral-vector production and scale-up strategies aimed at enabling high-dose throughput using modest bioreactor volumes.
Assay development and IND support
Development, qualification, and validation of virology and immunology assays to support IND filings and clinical development.
Preclinical efficacy testing and animal challenge studies
Design and execution of preclinical efficacy and challenge studies across multiple species to evaluate protective responses of vaccine candidates.
Process development and small-scale manufacturing for viral-vectored vaccines
Upstream process development for viral-vector production and scale-up strategies aimed at enabling high-dose throughput using modest bioreactor volumes.
Expertise Areas
- Intranasal vaccine development
- Viral vector platform engineering
- Preclinical animal challenge models
- Clinical trial design and execution (Phase 1–2)
Key Technologies
- PIV5-based viral vectors
- Intranasal spray delivery
- Mucosal (secretory) antibody induction
- Recombinant viral recovery and cDNA cloning